Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines
JAMA Network Open · 06.11.2024 · 7 (11) · e2443166
DOI: 10.1001/jamanetworkopen.2024.43166 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 06.11.2024. Verfasst von Emmanuel B Walter und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Influenza Vaccines, COVID-19, COVID-19 Vaccines, Vaccines, Inactivated. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Importance Limited randomized clinical trial data exist on the safety of simultaneous administration of COVID-19 and influenza vaccines.
Objective
To compare the reactogenicity, safety, and changes in health-related quality of life (HRQOL) after simultaneous vs sequential receipt of messenger RNA (mRNA) COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4). Design, Setting, and Participants This randomized, placebo-controlled clinical trial was conducted between October 8, 2021, and June 14, 2023, at 3 US sites. Participants were nonpregnant persons aged 5 years or older with the intention of receiving both influenza and mRNA COVID-19 vaccines.
Interventions
Intramuscular administration in opposite arms of either IIV4 or saline placebo simultaneously with mRNA COVID-19 vaccine at visit 1. Those who received placebo at visit 1 received IIV4 and those who received IIV4 at visit 1 received placebo 1 to 2 weeks later at visit 2. Main Outcomes and Measures The primary composite reactogenicity outcome was the proportion of participants with fever, chills, myalgia, and/or arthralgia of moderate or greater severity within 7 days after vaccination visits 1 and/or 2, using a 10% noninferiority margin. Secondary outcomes were solicited reactogenicity events and unsolicited adverse events (AEs) for 7 days after each visit separately and HRQOL after visit 1, assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index. Serious AEs (SAEs) and AEs of special interest (AESIs) were assessed for 121 days. Outcomes were compared between groups.
Results
A total of 335 persons (mean [SD] age, 33.4 [15.1] years) were randomized (169 to the simultaneous group and 166 to the sequential group); 211 (63.0%) were female, and 255 (76.1%) received bivalent BNT162b2 mRNA COVID-19 vaccine. The proportion with the primary composite reactogenicity outcome in the simultaneous group (25.6% [n = 43]) was noninferior to the proportion in the sequential group (31.3% [n = 52]) (site-adjusted difference, –5.6 percentage points [pp]; 95% CI, −15.2 to 4.0 pp). Respective proportions in each group were similar after each visit separately (visit 1, 40 [23.8%] vs 47 [28.3%]; visit 2, 5 [3.0%] vs 9 [5.4%]). No significant group differences in participants with AEs (21 [12.4%] vs 16 [9.6%]), SAEs (1 [0.6%] vs 1 [0.6%]), and AESIs (19 [11.2%] vs 9 [5.4%]) were observed in the simultaneous vs sequential groups, respectively. Among participants with severe reactogenicity, the mean (SD) EQ-5D-5L Index score decreased from 0.92 (0.08) to 0.92 (0.09) prevaccination to 0.81 (0.09) to 0.82 (0.12) postvaccination. Conclusions and Relevance In this randomized clinical trial assessing simultaneous vs sequential administration of mRNA COVID-19 and IIV4 vaccines, reactogenicity was comparable in both groups. These findings support the option of simultaneous administration of these vaccines. Trial Registration ClinicalTrials.gov Identifier: NCT05028361
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
- Duke Human Vaccine Institute, Durham, North Carolina.
- Division of Infectious Diseases, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
- Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Förderung
- NIA NIH HHS
Zitieren
APA
Walter, E. B., Schlaudecker, E. P., Talaat, K. R., Rountree, W., Broder, K. R., Duffy, J., Grohskopf, L. A., Poniewierski, M. S., Spreng, R. L., Staat, M. A., Tekalign, R., Museru, O., Goel, A., Davis, G. N., & Schmader, K. E. (2024). Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines. JAMA Network Open, 7(11), e2443166. https://doi.org/10.1001/jamanetworkopen.2024.43166
Vancouver
Walter EB, Schlaudecker EP, Talaat KR, Rountree W, Broder KR, Duffy J, et al. Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines. JAMA Network Open. 2024;7(11):e2443166. doi:10.1001/jamanetworkopen.2024.43166
BibTeX
@article{Walter2024,
author = {Walter, Emmanuel B and Schlaudecker, Elizabeth P and Talaat, Kawsar R and Rountree, Wes and Broder, Karen R and Duffy, Jonathan and Grohskopf, Lisa A and Poniewierski, Marek S and Spreng, Rachel L and Staat, Mary A and Tekalign, Rediet and Museru, Oidda and Goel, Anju and Davis, Grace N and Schmader, Kenneth E},
title = {Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {11},
pages = {e2443166},
doi = {10.1001/jamanetworkopen.2024.43166}
}
EUVIMED